COVID-19 ve Hipertansiyon

Abstract

On 31 December 2019, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in China, caused COVID-19 infection and a pandemic. Hypertension (HT) appeared as an important comorbidity affecting prognosis in COVID-19 infection. SARS-CoV-2's use of angiotensin converting enzyme 2 ('angiotensin converting enzyme-2' , ACE2) as viral entry receptor in the lung has caused concern in patients diagnosed with hypertension and receiving ACEI / ARB therapy in COVID-19 infection. Studies show that the disease is more serious and more mortal in HT patients diagnosed with COVID-19. Taking ACEI / ARB, does not differ prognosis and mortality in many studies and even has positive effects in some studies. In addition, it seems that other antihypertensive treatments do not make a significant difference in terms of prognosis or mortality. Blood pressure of hypertensive patients must be kept under control. If there is no other reason, antihypertensive treatments of patients should not be changed.